| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now.
|
|
Today’s Big NewsApr 29, 2025 |
| By Fraiser Kansteiner After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Aside from a sales slump fueled by a broader downturn in the VEGF medicine market, a crucial prefilled syringe version of the drug's high-dose format was rejected by the FDA last week, Regeneron said in an earnings release. |
|
|
|
By Gabrielle Masson The affected Cambridge site is Ono’s U.S. headquarters and one of the company's two locations in the country, with the other in San Francisco. |
By Conor Hale Roche’s companion diagnostic aims to identify non-small cell lung cancer patients who may benefit from Datroway, an antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo. |
By Andrea Park For the second year in a row, the pharmaceutical industry has dipped further out of favor with patient groups around the world. |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now.
|
|
By Zoey Becker The company added an extra $1.7 billion to its "cost realignment" drive, which was first announced in 2023. |
By Ben Adams Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio. |
By Conor Hale Designed for people with Type 1 diabetes, the companies said the launch of the combined system is slated for the third quarter of this year. |
By Nick Paul Taylor Bayer has overturned a ruling that it brought discredit on the pharma industry. Accused of “warming the market” for a new Eylea indication, the German drugmaker successfully argued on appeal that an advisory board was in fact legitimate. |
By Andrea Park Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. |
By Gabrielle Masson An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been delayed—again—this time, with no new decision date given. |
By Andrea Park The company announced the paper’s publication on Tuesday, National Fentanyl Awareness Day, touting its Opvee as an opioid overdose reversal medication that aligns with the expert panel’s recommendations. |
By Nick Paul Taylor Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. |
By Ben Adams AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear-out. |
By Angus Liu Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals get in the way of its progress. |
Fierce podcastsDon’t miss an episode |
| | Two journalists, one name and a candid conversation—Angus Liu and Angus Chen talk cancer reporting, racial identity and being mistaken for each other. |
|
|---|
|
|
|
Tuesday, May 20, 2025 | 11am ET / 8am PT This webinar will feature industry experts discussing the power of combining biomedical data analysis with matched tissue and molecular samples. Register today to learn more.
|
|
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| WhitepaperIs your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
| ResearchWe interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
